|Home | About | Journals | Submit | Contact Us | Français|
M.D. Anderson Cancer Center Announces the Funding of a SPORE in Brain Cancer
Under the leadership of the principal investigator, W. K. Alfred Yung, MD, and the co–principal investigator, Oliver Bögler, PhD, the Brain Tumor Center at the University of Texas M.D. Anderson Cancer Center has been named by the National Cancer Institute as a new Specialized Program of Research Excellence (SPORE) for the study of brain cancer. M.D. Anderson, in collaboration with the Mayo Clinic and the University of California at San Francisco, has gathered an outstanding multidisciplinary group of investigators whose research is both innovative and translational. The following projects and cores are funded under the SPORE mechanism:
Project 1: Tropism-Enhanced Oncolytic Adenovirus for the Treatment of Brain Tumors
Basic Biological Sciences Co-Leader: Juan Fueyo, MD
Applied Sciences Co-Leader: Frederick F. Lang, MD
Specific Aim 1: Determine the extent to which Delta-24-RGD can replicate in and spread through gliomas in situ in patients.
Specific Aim 2: Determine the extent to which Delta-24-RGD and temozolomide are synergistic antiglioma agents and examine the underlying mechanisms of the synergy.
Specific Aim 3: Determine the extent to which bone marrow–derived human mesenchymal stem cells can improve the delivery of Delta-24-RGD to gliomas.
Project 2: Targeting the PI3K Pathway in Gliomas with PI3K Inhibitors and Rational Combinations
Applied Sciences Co-Leader: W. K. Alfred Yung, MD
Basic Biological Sciences Co-Leader: Garth Powis, DPhil
Basic Biological Sciences Co-Leader: Oliver Bögler, PhD
Specific Aim 1: To study PX-866 and rational combinations in improved preclinical culture and animal models of glioma.
Specific Aim 2: To initiate clinical trials of PX-866 and rational combinations.
Specific Aim 3: To identify novel synergistic targets for rational drug combinations with PX-866 using siRNA synthetic lethality screening.
Project 3: Predicting Therapeutic Response in Glioblastoma and Targeting Refractory Tumors
Applied Sciences Co-Leader: Kenneth D. Aldape, MD
Applied Sciences Co-Leader: Howard Colman, MD, PhD
Basic Biological Sciences Co-Leader: Robert B. Jenkins, MD, PhD
Specific Aim 1: Evaluate the ability of a multigene panel to predict patient outcome (progression-free survival) in a retrospective sample of newly diagnosed glioblastoma multiforme (GBM) patients treated with standard therapy (TMZ-CR).
Specific Aim 2: Validate the multimarker predictor in a prospective, randomized phase III trial of >800 patients (Radiation Therapy Oncology Group 05–25) and identify additional robust molecular profiles of refractory tumors.
Specific Aim 3: Utilize samples from clinical trials of newly diagnosed GBM to test the extent to which the multigene set is predictive of response to new targeted therapies.
Project 4: Genetic Modulation of Cognitive Function and Outcomes in Glioblastoma Patients
Basic Biological Sciences Co-Leader: Melissa L. Bondy, PhD
Basic Biological Sciences Co-Leader: Christina A. Meyers, PhD
Basic Biological Sciences Co-Leader: Margaret R. Wrensch, PhD
Applied Sciences Co-Leader: Charles A. Conrad, MD
Applied Sciences Co-Leader: Susan M. Chang MD
Specific Aim 1: To create a customized single nucleotide polymorphism (SNP) chip (Golden Gate assay; Illumina platform) focusing on the neurocognitive, metabolizing, DNA repair, and inflammation genes relevant to neurocognitive outcome.
Specific Aim 2: To conduct neurocognitive evaluations on all patients treated and followed at each institution following the standardized testing established for a number of collaborative group–and pharmaceutical company–sponsored studies.
Specific Aim 3: To integrate the data derived from Aims 1 and 2 to determine if variants in the neurocognitive, metabolizing, DNA repair, and inflammation pathway genes alter the overall quality of life.
These projects are supported by the following cores:
Core A: Administrative; Co-Directors: Oliver Bögler, PhD, and W. K. Alfred Yung, MD
Core B: Pathology and Tissue Procurement; Co-Directors: Kenneth D. Aldape, MD, and Gregory N. Fuller, MD, PhD
Core C: Biostatistics; Director: Kenneth R. Hess, PhD
Core D: Clinical; Director: Mark R. Gilbert, MD
Core E: Animal; Co-Directors: Frederick F. Lang, MD, and Charles A. Conrad, MD
The SPORE also has Career Development and Developmental Research Programs.
Mechanisms of Neural Differentiation and Brain Tumors
July 30–August 5, 2008
Long Island, NY
Cold Spring Harbor Course, Co-sponsored by ABTA
For more information: http://meetings.cshl.edu/courses/c-braintumors08.shtml.
Sixth International Congress on Meningiomas and Cerebral Venous System
September 3–7, 2008
Late-breaking abstracts focus on unusually important results obtained after the March 28, 2008, regular abstract deadline. At press time, the Abstract Center was scheduled to reopen on May 15, 2008, and remain open until June 30, 2008.
Participate in an exciting opportunity to present the latest technology, techniques, and issues relevant to brain tumor research and therapy. You will be exposed to cutting-edge research and will have the chance to discuss cases and experiences with your peers at this truly unique meeting.
Peter Black, MD, PhD; Mark Johnson, MD, PhD; and the entire program planning committee have created an exceptional scientific and social program. Breakfast seminars, special sessions, oral presentations, interactive sessions, a specially arranged social event each evening, and an outstanding optional tour program make for an unforgettable meeting you will not want to miss.
For more information: http://www.themeningiomaconference2008.org.
Eighth Congress of EANO
September 12–14, 2008
The Eighth Congress of the European Association of Neuro-Oncology will take place under the auspices of the Spanish Group of Neuro-Oncology (GENO). GENO was founded in 1999 under the multidisciplinary spirit of EANO. The local organizing committee is already working hard with EANO to provide the best postgraduate course for the first day of the congress and an attractive scientific program that will cover the most important topics of the field in main symposia, meet-the-expert sessions, and keynote lectures. As usual, the interdisciplinary spirit will be the basis of the congress. Colleagues from all the neuro-oncological disciplines, such as basic sciences; neuropathology; neurology; neurosurgery; neuroimaging; medical, pediatric, and radiation oncology; and nursing are invited to participate actively at the oral and poster presentations.
For more information, contact Yannis Roussos by phone at +43 1 4051383-0 or visit http://www.eano.eu.
November 20–23, 2008
Lake Las Vegas Resort outside Las Vegas, NV
Fourth Fred J. Epstein International Symposium on Pediatric Neurology, Neurosurgery, and Neurofibromatosis
March 15–19, 2009
The symposium is in memory of Fred J. Epstein, MD, the founding director of the Institute for Neurology and Neurosurgery (INN) at Beth Israel Medical Center in New York City. Fred Epstein’s groundbreaking surgical techniques, and his commitment to humane patient care, earned him a reputation as the world’s leading pediatric neurosurgeon.
This event presents an update on the diagnoses and management of diseases of the nervous system in infants and children that may be treated surgically. Emphasis will be placed on joint, rather than parallel, sessions with both neurological and neurosurgical approaches. This gathering of professionals provides a unique opportunity for the dissemination of knowledge and experience. We hope that this meeting will bridge the gap in communication among various disciplines. For more information, contact Prof. Shlomi Constantini by phone at +3 517 5150 or visit http://www.fredhorizons.com.
World Federation of Neuro-Oncology 2009, jointly with the Sixth Meeting of the Asian Society for Neuro-Oncology
May 11–14, 2009
Pacifico Yokohama, Japan
On behalf of Prof. Masao Matsutani and organizers of the Asian Society for Neuro-Oncology, we are pleased to announce plans for the Third Quadrennial Meeting of the World Federation of Neuro-Oncology, in conjunction with the Sixth Meeting of the Asian Society for Neuro-Oncology. Details of the meeting will be made available on the Web site, http://wfno2009.umin.ne.jp, as they become available (note that the Web site currently shows the dates May 12–15, 2009, but the dates have been changed to May 11–14, 2009). For more information, contact Yoko Nishikawa Nobuko Baba by phone at +81 3-3589-4422 or by e-mail at pj.oc.xevnoc@9002onfw, or visit http://wfno2009.umin.ne.jp.
Please send all items you would like to have included here in future issues to Oliver Bögler, PhD, Brain Tumor Center and Dept. of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Unit BSRB 1004, Room S5.8136, 1515 Holcombe Blvd., Houston, TX 77030; phone (713) 834 6216; fax (713) 834 6257; e-mail gro.cno-oruen-cos@swenyteicos.